Trial Profile
GutHeart: Targeting Gut Microbiota to Treat Heart Failure
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Saccharomyces boulardii (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 05 Oct 2021 This trial has been completed in Norway, according to European Clinical Trials Database record.
- 25 Mar 2019 Planned End Date changed from 30 Dec 2019 to 31 Dec 2019.
- 25 Mar 2019 Planned primary completion date changed from 31 Dec 2018 to 20 Jun 2019.